TP53 and acute myeloid leukemia: Although NGS sequencing allowed to describe and clearly define the novel entity TP53 AML/AMDS-EB, the results of TP53 measurable residual disease (MRD) monitoring are disappointing since no correlation was observed with survival, despite using deep sequencing that detected MRD positivity in 73% of patients in complete remission (CR).